https://rijournals.com/public-health-and-pharmacy/

RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(3):37 -44, 2024

RIJPP Publications

ISSN ONLINE: 1115-8689

ISSN PRINT 1597-8559

https://doi.org/10.59298/RIJPP/2024/333744

HIV and Gut Microbiota: Understanding the Link between Immune Function, Inflammation, and Viral Persistence

Nyambura Achieng M.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Human immunodeficiency virus (HIV) infection was associated with significant alterations in gut microbiota, which in turn impacts immune function, inflammation, and viral persistence. This review explored the complex interplay between HIV and gut microbiota, highlighting how dysbiosis can lead to chronic immune activation and increased inflammation, factors that contribute to the persistence of the virus. This review comprehensively analised recent literature on gut microbiota composition in HIV-infected subjects, focusing on studies that assess the relationship between microbial diversity, immune function, and disease progression. The review also synthesizes findings from various studies that demonstrate shifts in microbial composition among HIV-infected individuals, correlating these changes with immune parameters such as CD4+ T cell counts and levels of viremia. Additionally, it discussed potential therapeutic strategies aimed at modulating gut microbiota to improve immune recovery and reduce inflammation in HIV patients.

Keywords: HIV infection, Gut microbiota dysbiosis, Immune dysfunction, Chronic inflammation, Viral persistence.

INTRODUCTION

The relationship between HIV and gut microbiota has emerged as a significant area of research, revealing complex interactions that impact immune function, inflammation, and disease progression [1-3]. The human gastrointestinal tract is home to a diverse community of microorganisms that play a crucial role in maintaining immune homeostasis [[4,5]. In individuals living with HIV, alterations in gut microbiota composition often referred to as dysbiosis have been observed, which can exacerbate immune dysfunction and systemic inflammation [6,7]. HIV infection leads to a profound depletion of CD4+ T cells, particularly in gut-associated lymphoid tissue, where approximately 60% of these cells reside [8,9]. This depletion disrupts the delicate balance of gut microbiota and impairs the host's ability to regulate immune responses effectively. As a result, the altered microbiota can contribute to increased intestinal permeability, allowing microbial translocation into the bloodstream, which further fuels chronic inflammation and immune activation [10,11]. Recent studies have indicated that the dysbiotic profiles associated with HIV infection are not merely a consequence of the virus but may also play a direct role in disease pathogenesis [12,13]. Factors such as lifestyle, diet, and co-infections complicate the understanding of these interactions, necessitating a nuanced approach to studying the gut microbiome in the context of HIV [14]. Moreover, the introduction of antiretroviral therapy (ART) has shown mixed effects on gut microbiota diversity, highlighting the need for ongoing research to elucidate the mechanisms through which gut microbiota influence HIV outcomes [15,16]. This review aims to provide an overview of the current understanding of the interplay between HIV and gut microbiota, emphasizing the implications for immune function, inflammation, and potential therapeutic interventions. By exploring these connections, we can better comprehend the role of gut microbiota in HIV pathogenesis and identify strategies to mitigate its adverse effects on health.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

HIV AND IMMUNE DYSREGULATION

HIV infection is characterized by significant immune dysregulation, primarily due to the depletion of CD4+ T cells, which are crucial for orchestrating immune responses. This dysregulation manifests as a persistent state of immune activation and inflammation, even in individuals receiving antiretroviral therapy (ART).

Mechanisms of Immune Dysregulation

i. **CD4+ T Cell Decline:** The hallmark of HIV infection is the gradual loss of CD4+ T cells, which compromises the immune system's ability to respond to infections and malignancies [17]. The extent of CD4+ T cell depletion correlates with the severity of immune dysfunction and the risk of opportunistic infections [18].

ii. ***Chronic Inflammation:*** HIV infection leads to a chronic inflammatory state characterized by elevated levels of pro-inflammatory cytokines, such as IL-6 and TNF-α. This inflammation persists despite effective viral suppression with ART, contributing to non-AIDS-related comorbidities, including cardiovascular disease and metabolic syndrome [19,20]

iii. ***Immune Activation:*** Persistent immune activation is observed in HIV-infected individuals, even those on ART [21]. Biomarkers of immune activation, such as CD38 and HLA-DR expression on T cells, are elevated and have been associated with poor health outcomes. This activation is thought to be driven by ongoing low-level viral replication, microbial translocation from the gut, and the effects of chronic inflammation.

iv. ***B Cell Dysfunction:*** HIV also induces defects in humoral immunity, characterized by altered B cell activation and reduced antibody responses. This dysfunction can lead to increased susceptibility to infections and decreased vaccine efficacy, posing additional challenges for managing health in HIV-infected individuals [22].

Implications for Health Outcomes

The consequences of immune dysregulation in HIV are profound, leading to increased morbidity and mortality. Chronic inflammation and immune activation are now recognized as critical factors that contribute to the long-term health issues faced by people living with HIV. This has shifted the focus of HIV research from merely controlling viral load to understanding and mitigating the effects of immune dysregulation.

THE ROLE OF GUT MICROBIOTA

The gut microbiota plays a crucial role in maintaining immune homeostasis and influencing systemic immune responses [23]. In HIV-infected individuals, alterations in gut microbiota composition have been observed, often referred to as dysbiosis. This complex community of microorganisms, residing primarily in the gastrointestinal tract, interacts dynamically with the host's immune system, contributing to various physiological functions and disease processes. This dysbiosis is associated with increased intestinal permeability, allowing microbial translocation into the systemic circulation, which further exacerbates immune activation and inflammation [25].

Dysbiosis and Disease: Alterations in gut microbiota composition, known as dysbiosis, can lead to immune dysregulation and are associated with various diseases, including autoimmune disorders, inflammatory bowel disease, and even some cancers [26]. Dysbiosis may result from factors such as antibiotic use, diet, and environmental changes, which can disrupt the delicate balance of microbial communities and trigger inflammatory responses [27].

Immune Development and Regulation: Gut microbiota is essential for the development and functional maturation of the immune system. In germ-free (GF) animal models, the absence of microbiota results in underdeveloped gut-associated lymphoid tissues and a reduced number of immune cells, highlighting the microbiota's role in training the immune system. Commensal bacteria promote the differentiation of T helper cells, regulatory T cells, and IgA-producing B cells, which are vital for both local and systemic immune responses [28].

Mechanisms of Gut Microbiota Influence

i. ***Immune Modulation:*** Gut microbiota can influence the differentiation and function of various immune cells, including T cells and dendritic cells [23]. Certain microbial metabolites, such as short-chain fatty acids (SCFAs), have been shown to promote anti-inflammatory responses, potentially counteracting the chronic inflammation seen in HIV infection [29].

ii. ***Inflammatory Cytokine Production:*** Dysbiosis can lead to increased production of pro-inflammatory cytokines, such as TNF-α and IL-6, which are implicated in the pathogenesis of HIV. These cytokines contribute to systemic inflammation and can further impair immune function, creating a vicious cycle that enhances viral persistence [31].

iii. ***Antigen Presentation:*** The gut microbiota influences the ability of antigen-presenting cells (APCs) to effectively present viral antigens to T cells. Alterations in microbial composition may impair the activation of CD4+ T cells, leading to ineffective immune responses against HIV [32].

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

INFLAMMATION AND VIRAL PERSISTENCE

Inflammation and viral persistence are intricately linked processes that significantly impact the pathogenesis of chronic viral infections, including HIV. Persistent viral infections are characterized by the virus's ability to evade host immune responses, leading to sustained viral replication and ongoing inflammation, which can result in tissue damage and immune dysregulation.

Mechanisms of Viral Persistence: Viruses such as HIV establish persistence through various mechanisms, including the formation of viral reservoirs in long-lived cells and tissues [33]. These reservoirs allow the virus to remain latent or replicate at low levels, continuously stimulating the immune system. In HIV-infected individuals, even with effective antiretroviral therapy (ART), low-level viral replication can persist, contributing to chronic immune activation. This ongoing immune stimulation is often marked by elevated levels of inflammatory cytokines and immune cell activation, which can lead to a cycle of inflammation that exacerbates tissue damage and hinders effective immune responses [34,35].

Role of Inflammation: The inflammatory response to persistent viral infections is multifaceted. On one hand, inflammation is necessary for controlling viral replication and clearing infected cells. However, chronic inflammation can lead to detrimental effects, including:

i. ***Immune Exhaustion:*** Prolonged exposure to viral antigens can result in T cell exhaustion, characterized by reduced functionality and increased expression of inhibitory receptors such as PD-1. This exhaustion impairs the immune system's ability to effectively respond to the virus and contributes to viral persistence [36].

ii. ***Tissue Damage:*** Persistent inflammation can cause damage to host tissues, as inflammatory cytokines and immune cells can lead to cellular injury and dysfunction. This is particularly evident in HIV, where chronic inflammation is associated with increased risk of comorbidities, such as cardiovascular disease and metabolic disorders [37].

iii. ***Dysregulated Immune Responses:*** Chronic inflammation can disrupt the balance of immune responses, leading to a state of immune dysregulation. This dysregulation can hinder the development of effective memory responses, making individuals more susceptible to opportunistic infections and other diseases [38].

Implications for Treatment: Understanding the relationship between inflammation and viral persistence is crucial for developing effective therapeutic strategies. Interventions aimed at reducing inflammation, such as the use of anti-inflammatory agents or immunomodulators, may enhance the immune response and help control viral replication. Additionally, targeting the viral reservoirs and improving immune function through strategies like therapeutic vaccines could provide new avenues for managing chronic viral infections [39,40].

GUT-RELATED INFLAMMATION

Gut-related inflammation is a significant concern in various health conditions, particularly due to its role in chronic diseases and immune dysregulation. This inflammation arises from a complex interplay between the gut microbiota, dietary factors, infections, and the host's immune response.

Mechanisms of Gut Inflammation

i. ***Microbial Dysbiosis:*** The gut microbiota consists of a diverse array of microorganisms that contribute to immune regulation and metabolic processes [41]. Dysbiosis, characterized by an imbalance in microbial composition, can trigger inflammatory responses. For instance, an increase in pro-inflammatory bacteria and a decrease in anti-inflammatory species can lead to heightened immune activation and chronic inflammation, as seen in conditions like inflammatory bowel disease (IBD) and HIV infection [42].

ii. ***Increased Intestinal Permeability:*** Inflammation can compromise the integrity of the intestinal barrier, leading to increased permeability or "leaky gut." This allows microbial products, such as lipopolysaccharides (LPS), to enter the bloodstream, further stimulating systemic inflammation and contributing to conditions like metabolic syndrome and cardiovascular diseases [43].

iii. ***Immune Activation:*** The presence of pathogens, dietary antigens, or altered microbiota can activate the immune system, resulting in the release of inflammatory cytokines. These cytokines, such as IL-6 and TNF-α, play a key role in mediating inflammation and can lead to tissue damage if the inflammatory response becomes chronic [44,45].

Implications of Gut Inflammation

Chronic gut inflammation is associated with various health issues, including:

i. ***Autoimmune Disorders:*** Conditions like Crohn's disease and ulcerative colitis are characterized by persistent gut inflammation, leading to significant morbidity and altered quality of life [46].

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

ii. ***Metabolic Disorders:*** Gut inflammation has been linked to insulin resistance and obesity, as inflammatory mediators can interfere with metabolic pathways and contribute to systemic inflammation [47].

iii. ***HIV and Chronic Inflammation:*** In HIV-infected individuals, gut dysbiosis and persistent inflammation are common, even with effective antiretroviral therapy. This chronic inflammation is associated with increased risk of comorbidities, highlighting the need for strategies to restore gut health and mitigate inflammation [48].

IMPLICATIONS FOR TREATMENT

The implications for treatment in the context of HIV are multifaceted, focusing on managing the virus effectively while addressing the challenges of viral persistence and immune dysregulation. Current strategies primarily revolve around antiretroviral therapy (ART), innovative research toward potential cures, and holistic patient care approaches [49].

Antiretroviral Therapy (ART): ART remains the cornerstone of HIV treatment, involving a combination of at least three antiretroviral medications from different classes to suppress viral load and maintain immune function [50]. Effective ART can reduce HIV to undetectable levels in the blood, significantly improving the quality of life and longevity for individuals living with HIV [51]. Importantly, achieving and maintaining an undetectable viral load also prevents sexual transmission of the virus, a concept encapsulated in the "Undetectable = Untransmittable" (U=U) campaign [52]. However, ART does not eradicate the virus, and individuals must adhere to lifelong treatment to prevent viral rebound upon discontinuation.

Research Towards a Cure: Despite the effectiveness of ART, the search for a functional or complete cure for HIV continues. Various strategies are being explored, including:

i. ***Latency-Reversing Agents (Kick and Kill):*** These aim to activate latent HIV reservoirs, allowing the immune system to target and eliminate infected cells [53].

ii. ***Gene Therapy:*** Approaches such as CRISPR are being investigated to edit the genome of infected cells or enhance the immune response against HIV [54].

iii. ***Immune-Based Therapies:*** These strategies focus on boosting the immune system's ability to control or eliminate HIV without the need for continuous ART [55].

iv. ***Combination Approaches:*** The complexity of HIV persistence necessitates a combination of strategies to effectively target different mechanisms of viral latency and immune dysfunction [56]

Holistic Patient Care: In addition to pharmacological interventions, holistic approaches to patient care are crucial. Strategies such as patient navigation and care team coordination enhance adherence to treatment, improve health outcomes, and address social determinants of health. These approaches provide comprehensive support, ensuring that individuals living with HIV receive the necessary resources and education to manage their health effectively [57,58].

CONCLUSION

The relationship between HIV and gut microbiota is critical in understanding the mechanisms underlying immune dysfunction, chronic inflammation, and viral persistence in infected individuals. Dysbiosis, characterized by an imbalance in microbial composition, has been consistently observed in HIV patients, leading to increased levels of proinflammatory bacteria and a decrease in beneficial anaerobic species. This shift contributes to systemic inflammation and immune activation, which are significant factors in HIV disease progression and the persistence of the virus despite antiretroviral therapy. Emerging therapeutic strategies, such as fecal microbiota transplantation and targeted probiotics, show promise in restoring gut microbiota balance and mitigating inflammation. Continued research is essential to elucidate the complex interactions between gut microbiota and HIV, which could lead to innovative treatment approaches aimed at improving immune function and reducing inflammation in HIV-infected individuals. Overall, addressing gut microbiota dysbiosis may play a pivotal role in enhancing the health outcomes of those living with HIV.

REFERENCES

1. Vujkovic-Cvijin I, Somsouk M. HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration. Curr HIV/AIDS Rep. 2019 Jun;16(3):204-213. doi: 10.1007/s11904-019-00441-w. PMID: 31037552
2. Wiertsema SP, van Bergenhenegouwen J, Garssen J, Knippels LMJ. The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies. Nutrients. 2021 Mar 9;13(3):886. doi: 10.3390/nu13030886. PMID: 33803407
3. Alum, E. U., Obeagu, E. I., Ugwu, O. P. C., Samson, A. O., Adepoju, A. O., Amusa, M. O. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

(Baltimore). 2023;102(41):e35673. http://dx.doi.org/10.1097/MD.0000000000035673.PMID: 37832059; PMCID: PMC10578718.

4. Tihong Shao, Ronald Hsu, Desiree L. Rafizadeh, Li Wang, Christopher L. Bowlus, Narendra Kumar, Jayshree Mishra, Suraj Timilsina, William M. Ridgway, M. Eric Gershwin, Aftab A. Ansari, Zongwen Shuai, Patrick S.C. Leung, The gut ecosystem and immune tolerance, Journal of Autoimmunity, 2023; 141: 103114. https://doi.org/10.1016/j.jaut.2023.
5. Zilberman-Schapira, G., Zmora, N., Itav, S. *et al.* The gut microbiome in human immunodeficiency virus infection. *BMC Med* 14, 83 (2016). https://doi.org/10.1186/s12916-016-0625-3
6. 6 Salvador PBU, Altavas PJDR, Del Rosario MAS, Ornos EDB, Dalmacio LMM. Alterations in the Gut Microbiome Composition of People Living with HIV in the Asia-Pacific Region: A Systematic Review. Clin Pract. 2024 May 15;14(3):846-861. doi: 10.3390/clinpract14030066. PMID: 38804398.
7. Alum, E. U.,Ugwu, O. P.C., Obeagu, E. I. and Okon, M. B. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*, 2023; 3(2): 28-31.https://nijournals.org/wp-content/uploads/2023/06/NIJRMS-32-28-31-2023-rm.pdf
8. Février M, Dorgham K, Rebollo A. CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses. 2011 May;3(5):586-612. doi: 10.3390/v3050586. Epub 2011 May 12. PMID: 21994747
9. Obeagu, E.I., Alum, E.U. and Obeagu, G.U. Factors Associated with Prevalence of HIV Among Youths: A Review of Africa Perspective. *Madonna University Journal of Medicine and Health Sciences*, 2023;**3**(1): 13-18.https://madonnauniversity.edu.ng/journals/index.php/medicine
10. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I., Aja, P. M., Okon, M. B., Uti, D. E. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023; 11(10):01-06. DOI:10.58538/IJIAR/2048. http://dx.doi.org/10.58538/IJIAR/2048
11. Fakharian F, Thirugnanam S, Welsh DA, Kim W-K, Rappaport J, Bittinger K, Rout N. The Role of Gut Dysbiosis in the Loss of Intestinal Immune Cell Functions and Viral Pathogenesis. *Microorganisms*. 2023; 11(7):1849. https://doi.org/10.3390/microorganisms11071849
12. Alum, E. U., Obeagu, E. I., Ugwu, O. P.C., Aja, P. M. and Okon, M. B. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*, 2023; 3(2): 95-99. https://nijournals.org/wp-content/uploads/2023/07/NIJRMS-3-295-99-2023.pdf.
13. Ishizaka, A., Koga, M., Mizutani, T. *et al.* Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV. *BMC Microbiol* 24, 6 (2024). https://doi.org/10.1186/s12866-023-03157-5
14. Obeagu, E. I., Nwosu, D. C., Ugwu, O. P. C. and Alum, E. U. Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES). 2023; 4(1):43-47. https://doi.org/10.59298/NIJSES/2023/10.6.1000
15. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Anemia as a Prognostic Marker for Disease Progression in HIV Infection. *IAA Journal of Biological Sciences*. 2023; 11(1):33-44.https://doi.org/10.59298/IAAJB/2023/3.2.23310
16. Annavajhala MK, Khan SD, Sullivan SB, Shah J, Pass L, Kister K, Kunen H, Chiang V, Monnot GC, Ricupero CL, Mazur RA, Gordon P, de Jong A, Wadhwa S, Yin MT, Demmer RT, Uhlemann AC. Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy. mSphere. 2020 Feb 5;5(1):e00798-19. doi: 10.1128/mSphere.00798-19. PMID: 32024712
17. Vidya Vijayan KK, Karthigeyan KP, Tripathi SP, Hanna LE. Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections. Front Immunol. 2017 May 23;8:580. doi: 10.3389/fimmu.2017.00580. PMID: 28588579; PMCID: PMC5440548.
18. Masenga SK, Mweene BC, Luwaya E, Muchaili L, Chona M, Kirabo A. HIV–Host Cell Interactions. *Cells*. 2023; 12(10):1351. https://doi.org/10.3390/cells12101351
19. Lv T, Cao W, Li T. HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies. J Immunol Res. 2021 Sep 29;2021:7316456. doi: 10.1155/2021/7316456. PMID: 34631899; PMCID: PMC8494587.
20. Luana Silva Soares, Milena Sobral Espíndola, Fabiana Albani Zambuzi, Leonardo Judson Galvão-Lima, Maira Costa Cacemiro, Murilo Racy Soares, Bárbara A. Santana, Rodrigo T. Calado, Valdes Roberto Bollela, Fabiani Gai Frantz, Immunosenescence in chronic HIV infected patients impairs essential

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

functions of their natural killer cells, International Immunopharmacology, 2020; 84, 106568. https://doi.org/10.1016/j.intimp.2020.106568.

21. Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses. 2019 Feb 27;11(3):200. doi: 10.3390/v11030200. PMID: 30818749; PMCID: PMC6466530.
22. Emmanuel Ifeanyi Obeagu, Nwanganga Ihuoma Ubosi, Getrude Uzoma Obeagu, Hauwa Ali Buhari and Simeon Ikechukwu Egba (2023) Storms and struggles: Managing HIV Amid Natural Disasters Int. J. Curr. Res. Chem. Pharm. Sci. (2023). 10(11): 14-25
23. Brenchley, J.M., Serrano-Villar, S. From dysbiosis to defense: harnessing the gut microbiome in HIV/SIV therapy. *Microbiome* **12**, 113 (2024). https://doi.org/10.1186/s40168-024-01825-w
24. Jennifer A. Fulcher, Fan Li, Nicole H. Tobin, Sara Zabih, Julie Elliott, Jesse L. Clark, Richard D'Aquila, Brian Mustanski, Michele D. Kipke, Steven Shoptaw, Pamina M. Gorbach, Grace M. Aldrovandi, Gut dysbiosis and inflammatory blood markers precede HIV with limited changes after early seroconversion, eBioMedicine, 2022; 84, 104286. https://doi.org/10.1016/j.ebiom.2022.104286.
25. Shaheen WA, Quraishi MN, Iqbal TH. Gut microbiome and autoimmune disorders. Clin Exp Immunol. 2022 Aug 19;209(2):161-174. doi: 10.1093/cei/uxac057. PMID: 35652460; PMCID: PMC9390838.
26. Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, Che T, Zhang C. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens. 2019 Aug 13;8(3):126. doi: 10.3390/pathogens8030126. PMID: 31412603; PMCID: PMC6789542.
27. Min'an Zhao, Jiayi Chu, Shiyao Feng, Chuanhao Guo, Baigong Xue, Kan He, Lisha Li, Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review, Biomedicine & Pharmacotherapy, 2023; 164, 114985 https://doi.org/10.1016/j.biopha.
28. Di Vincenzo, F., Del Gaudio, A., Petito, V. *et al.* Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. *Intern Emerg Med* **19**, 275–293 (2024). https://doi.org/10.1007/s11739-023-03374-w
29. Shim JA, Ryu JH, Jo Y, Hong C. The role of gut microbiota in T cell immunity and immune mediated disorders. Int J Biol Sci. 2023 Feb 13;19(4):1178-1191. doi: 10.7150/ijbs.79430. PMID: 36923929; PMCID: PMC10008692.
30. Alum EU, Uti DE, Ugwu OP, Alum BN. Toward a cure-Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review. Medicine (Baltimore). 2024 Jul 5;103(27):e38768. doi: 10.1097/MD.0000000000038768. PMID: 38968496.
31. Mazzuti L, Turriziani O, Mezzaroma I. The Many Faces of Immune Activation in HIV-1 Infection: A Multifactorial Interconnection. *Biomedicines*. 2023; 11(1):159. https://doi.org/10.3390/biomedicines11010159
32. Chen J, Zhou T, Zhang Y, Luo S, Chen H, Chen D, Li C, Li W. The reservoir of latent HIV. Front Cell Infect Microbiol. 2022 Jul 28;12:945956. doi: 10.3389/fcimb.2022.945956. PMID: 35967854; PMCID: PMC9368196.
33. Obeagu, E. I., Obeagu, G. U., Odo, E. O., Igwe, M. C., Ugwu, O. P. C., Alum, E. U. and Okwaja, P. R. Nutritional Approaches for Enhancing Immune Competence in HIV-Positive Individuals: A Comprehensive Review.*IDOSR JOURNAL OF APPLIED SCIENCES*. 2024; 9(1)40-50.https://doi.org/10.59298/IDOSRJAS/2024/1.7.8.295
34. Chou TC, Maggirwar NS, Marsden MD. HIV Persistence, Latency, and Cure Approaches: Where Are We Now? *Viruses*. 2024; 16(7):1163. https://doi.org/10.3390/v16071163
35. Mbonye, U., Karn, J. The cell biology of HIV-1 latency and rebound. *Retrovirology* **21**, 6 (2024). https://doi.org/10.1186/s12977-024-00639-w
36. Obeagu, E. I., Obeagu, G. U., Ugwu, O. P. C. and Alum, E. U. Navigating Hemolysis in Expectant Mothers with Sickle Cell Anemia: Best Practices and Challenges. *IAA Journal of Applied Sciences*. 2024; 11(1):30-39. https://doi.org/10.59298/IAAJAS/2024/4.78.99.11
37. 37 Jenkins E, Whitehead T, Fellermeyer M, Davis SJ, Sharma S. The current state and future of T-cell exhaustion research. Oxf Open Immunol. 2023 Jul 8;4(1):iqad006. doi: 10.1093/oxfimm/iqad006. PMID: 37554723; PMCID: PMC10352049.
38. Megha KB, Joseph X, Akhil V, Mohanan PV. Cascade of immune mechanism and consequences of inflammatory disorders. Phytomedicine. 2021 Oct;91:153712. doi: 10.1016/j.phymed.2021.153712. Epub 2021 Aug 19. PMID: 34511264; PMCID: PMC8373857.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

39. Shive C, Pandiyan P. Inflammation, Immune Senescence, and Dysregulated Immune Regulation in the Elderly. Front Aging. 2022 Apr 27;3:840827. doi: 10.3389/fragi.2022.840827. PMID: 35821823; PMCID: PMC9261323.
40. Seiler, A., Fagundes, C.P., Christian, L.M. (2020). The Impact of Everyday Stressors on the Immune System and Health. In: Choukèr, A. (eds) Stress Challenges and Immunity in Space. Springer, Cham. https://doi.org/10.1007/978-3-030-16996-1_6
41. Obeagu, E. I., Obeagu, G. U., Odo, E. O., Igwe, M. C., Ugwu, O. P. C., Alum, E. U. and Okwaja, P. R.Revolutionizing HIV Prevention in Africa: Landmark Innovations that Transformed the Fight. *IAA Journal of Applied Sciences*. 2024; 11(1):1-12. https://doi.org/10.59298/IAAJAS/2024/1.3.5288
42. Kim, S., Seo, SU. & Kweon, MN. Gut microbiota-derived metabolites tune host homeostasis fate. *Semin Immunopathol* **46**, 2 (2024). https://doi.org/10.1007/s00281-024-01012-x
43. Oliphant, K., Allen-Vercoe, E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. *Microbiome* **7**, 91 (2019). https://doi.org/10.1186/s40168-019-0704-8
44. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Understanding the Impact of HIV-Associated Bone Marrow Alterations on Erythropoiesis. *INOSR Scientific Research*. 2023; 10(1):1-11. https://doi.org/10.59298/INOSRSR/2023/1.2.12222
45. Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut Microbiota and Immune System Interactions. Microorganisms. 2020 Oct 15;8(10):1587. doi: 10.3390/microorganisms8101587. Erratum in: Microorganisms. 2020 Dec 21;8(12):E2046. doi: 10.3390/microorganisms8122046. PMID: 33076307; PMCID: PMC7602490.
46. David S. Kotlyar, Wojciech C. Blonski, Gary R. Lichtenstein, Chapter 338 - Advances in Understanding the Pathogenesis of Inflammatory Bowel Disease, Editor(s): Ralph A. Bradshaw, Edward A. Dennis, Handbook of Cell Signaling (Second Edition), Academic Press, 2010. pp 2945-2957. https://doi.org/10.1016/B978-0-12-374145-5.00338-7.
47. Alessandro Armuzzi, Giuseppina Liguori, Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review, Digestive and Liver Disease, 2021; 53(7): 803-808. https://doi.org/10.1016/j.dld.2021.03.002.
48. Ahluwalia, B., Moraes, L., Magnusson, M. K., & Öhman, L. (2018). Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. *Scandinavian Journal of Gastroenterology*, *53*(4), 379–389. https://doi.org/10.1080/00365521.2018.1447597
49. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine (Baltimore). 2024 Mar 1;103(9):e37354. doi: 10.1097/MD.0000000000037354. PMID: 38428854; PMCID: PMC10906605.
50. Wu, F., Simonetti, F.R. Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure. *Curr HIV/AIDS Rep* **20**, 428–439 (2023). https://doi.org/10.1007/s11904-023-00674-w
51. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Persistent Immune Activation and Chronic Inflammation: Unraveling Their Impact on Anemia in HIV Infection. *INOSR Experimental Sciences*. 2023; 12(3):73-84. https://doi.org/10.59298/INOSRES/2023/7.3.21322
52. Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV AIDS (Auckl). 2012;4:117-24. doi: 10.2147/HIV.S32321. Epub 2012 Aug 6. PMID: 22893751; PMCID: PMC3418767.
53. Hussein M, Molina MA, Berkhout B, Herrera-Carrillo E. A CRISPR-Cas Cure for HIV/AIDS. Int J Mol Sci. 2023 Jan 13;24(2):1563. doi: 10.3390/ijms24021563. PMID: 36675077; PMCID: PMC9863116.
54. Xiao Q, Guo D, Chen S. Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy. Front Cell Infect Microbiol. 2019 Mar 22;9:69. doi: 10.3389/fcimb.2019.00069. PMID: 30968001; PMCID: PMC6439341.
55. Zhihao Zhang, Wei Hou, Shuliang Chen, Updates on CRISPR-based gene editing in HIV-1/AIDS therapy, Virologica Sinica, 2022; 37(1): 1-10.https://doi.org/10.1016/j.virs.2022.01.017.
56. Margolis DM, Archin NM, Cohen MS, Eron JJ, Ferrari G, Garcia JV, Gay CL, Goonetilleke N, Joseph SB, Swanstrom R, Turner AW, Wahl A. Curing HIV: Seeking to Target and Clear Persistent Infection. Cell. 2020 Apr 2;181(1):189-206. doi: 10.1016/j.cell.2020.03.005. Epub 2020 Mar 26. PMID: 32220311; PMCID: PMC7896558.
57. David M. Margolis, Nancie M. Archin, Myron S. Cohen, Joseph J. Eron, Guido Ferrari, J. Victor Garcia, Cynthia L. Gay, Nilu Goonetilleke, Sarah B. Joseph, Ronald Swanstrom, Anne-Marie W. Turner, Angela

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Wahl, Curing HIV: Seeking to Target and Clear Persistent Infection, Cell, 2020; 181(1): 189-206. https://doi.org/10.1016/j.cell.2020.03.005.

58. Sadowski, I., Hashemi, F.B. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs. *Cell. Mol. Life Sci.* **76**, 3583–3600 (2019). https://doi.org/10.1007/s00018-019-03156-8

CITE AS: Nyambura Achieng M. (2024). HIV and Gut Microbiota: Understanding the Link between Immune Function, Inflammation, and Viral Persistence. RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(3): 37-44. https://doi.org/10.59298/RIJPP/2024/333744

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited